di-tert-butyl L-α-aminoadipate | 581785-29-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: di-tert-butyl L-α-aminoadipate
• 英文别名: aad(O-tert-Bu)2；L-2-aminoadipic acid di-tertbutyl ester；L-homoglutamic acid ditertiary butyl ester；Di-tert-butyl (S)-2-aminohexanedioate；ditert-butyl (2S)-2-aminohexanedioate
• CAS: 581785-29-7
• 化学式: C₁₄H₂₇NO₄
• 分子量: 273.373
• InChiKey: GADCOXFZALWVJI-JTQLQIEISA-N

物化性质

• 沸点：
  324.8±27.0 °C(Predicted)
• 密度：
  1.009±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  di-tert-butyl L-α-aminoadipate 在 三乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (2S)-2-amino-5-(4-cyano-3-fluorobenzyl)hexanedioic acid
  参考文献：
  名称：

  [EN] HOMOGLUTAMIC ACID DERIVATIVES
  [FR] DÉRIVÉS DE L'ACIDE HOMOGLUTAMIQUE

  摘要：

  本发明涉及适用于标记或已经标记为18F或19F的同谷氨酸衍生物，制备这类化合物的方法，包含这类化合物的组合物，包含这类化合物或组合物的试剂盒以及这类化合物、组合物或试剂盒用于诊断成像的用途。

  公开号：

  WO2011057986A1
• 作为产物：
  描述：

  醋酸叔丁酯 、 L-2-氨基己二酸 在 高氯酸 作用下， 以59%的产率得到di-tert-butyl L-α-aminoadipate
  参考文献：
  名称：

  设计和合成包含桥接酯基的二氢叶酸还原酶抑制剂。在小鼠结肠炎模型中的评估。

  摘要：

  克罗恩氏病是一种慢性炎症性肠病，其特征是小肠和大肠都发炎。甲氨蝶呤（MTX）是一种经典的二氢叶酸还原酶（DHFR）抑制剂，近年来已被用作克罗恩病患者的治疗剂。我们试图开发结构类似于MTX的抗叶酸药，该药可有效减轻结肠炎的小鼠疾病模型中的炎症。合成了在分子中心部分包​​含酯桥的四种经典DHFR抑制剂。这些抗叶酸剂是源自大鼠的DHFR酶的有效抑制剂。还体外测试了它们抑制小鼠脾淋巴细胞诱导的增殖的能力。仅在微摩尔范围内才能达到抑制细胞增殖的作用，而MTX在低纳摩尔浓度下有效。选择一种DHFR抑制剂（1），其rlDHFR的IC（50）值比甲氨蝶呤高约8倍，用于小鼠实验性结肠炎模型的体内实验。该化合物在局部给药后表现出明显的抗炎作用，与糖皮质激素布地奈德所达到的作用相当。在该模型中评估了三个参数：髓过氧化物酶活性，结肠重量和炎症评分。在所有三个炎症参数中均观察到化合物1的体内有益作用（15 mg /（kg

  DOI：

  10.1021/jm021062y

文献信息

• Method and composition for treating osteoporosis
  申请人：Rao Venkata Subba Kanury

  公开号：US20050085537A1

  公开（公告）日：2005-04-21

  This invention relates to a novel class of acidic amino acid/dicarboxylic acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids and their amides) useful as inhibitors of osteoclastogenesis. The invention also provides methods of using the novel class of acidic amino acid/dicarboxylic acid derivatives of the general formula ZOC—(CRR) m —COOH, wherein: m= 2, 3 or 4 ; Z is OH or NH 2 ; one R in the compound is from the group consisting of SO 3 H, OSO 3 H, CH 2 —SO 3 H, CH 2 —OSO 3 H, and NHSO 3 H, and the remaining Rs are H or NH 2 , for inhibition of osteoclastogenesis.

  这项发明涉及一类新型的酸性氨基酸/二羧酸衍生物（天然氨基酸及其酰胺的磺酸/硫酸酯衍生物），用作抑制破骨细胞生成。该发明还提供了使用一般式为ZOC—(CRR)m—COOH的新型酸性氨基酸/二羧酸衍生物的方法，其中：m=2、3或4；Z为OH或NH2；化合物中的一个R来自包括SO3H、OSO3H、CH2—SO3H、 —OSO3H和NHSO3H的群体，其余的R为H或NH2，用于抑制破骨细胞生成。
• The Synthesis and Thymidylate Synthase Inhibitory Activity of L-.gamma.-L-Linked Dipeptide and L-.gamma.-Amide Analogs of 2-Desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
  作者：Graham M. F. Bisset、Vassilios Bavetsias、Timothy J. Thornton、Krzysztof Pawelczak、A. Hilary Calvert、Leslie R. Hughes、Ann L. Jackman

  DOI：10.1021/jm00046a014

  日期：1994.9

  Sixteen gamma-linked dipeptide and four L-Glu-gamma-amide analogues of 2-desamino-2-methyl-N-10-propargyl-5,8-dideazafolic acid (ICI 198583) have been synthesized and evaluated as inhibitors of thymidylate synthase (TS). Z-blocked L-Glu-gamma-L-linked dipeptides and L-Glu-gamma-amides were prepared by condensing alpha-tert-butyl-N-(benzyloxycarbonyl)-L-glutamic acid with the appropriate tert-butyl-protected L-amino acid or amine. The Z group was removed by catalytic hydrogenolysis, and the resulting dipeptides or L-Glu-gamma-amides were condensed with the appropriate pteroic acid analogue trifluoroacetate salt using diethyl cyanophosphoridate as coupling reagent. Deprotection with trifluoroacetic acid in the final step gave the desired quinazoline gamma-linked dipeptides and L-Glu-gamma-amides as their trifluoroacetate salts. Nearly all the dipeptide analogues were potent inhibitors of TS, the best being ICI 198583-gamma-L-2-aminoadipate (IC50 = 2 nM). Several of these dipeptides were found to be susceptible to enzymatic hydrolysis in mice. The quinazoline monocarboxylate L-Glu-gamma-amides, lacking an alpha'-carboxyl group, are less active against TS and L1210 cell growth but are also not susceptible to enzymatic hydrolysis in mice.
• CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
  申请人：ENDOCYTE, INC.

  公开号：US20210154311A1

  公开（公告）日：2021-05-27

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
• CANCER DIAGNOSTIC IMAGING AGENTS
  申请人：Technische Universität München

  公开号：US20220118120A1

  公开（公告）日：2022-04-21

  The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.
• [EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：[en]PROVINCIAL HEALTH SERVICES AUTHORITY

  公开号：WO2024016071A1

  公开（公告）日：2024-01-25

  The present disclosure relates to prostate specific membrane antigen (PSMA)-targeting compounds of formula (I) or of a salt or a solvate thereof. The PSMA-targeting compounds of the present disclosure can be useful as imaging agents for PSMA-expressing diseases/conditions.